Recently, the European Medicines Agency (EMA) sent out a survey to its stakeholders asking for their opinion regarding a new clinical trials database design.
The rationale for EMA asking its stakeholders for their opinions is due to new regulations that were created in April 2014 that will be in effect next year. The old regulations allowed the EMA to share requested information but also keep some information confidential. Now, with the new regulations, there will be a change in how the trials are done and what information can be submitted.
To find out more on the survey the EMA sent out, read the full article.